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Reduced genomes in nature 
Gene loss occurs naturally as a result of sudden mutation or as a slow process 
where mutations have acummulated1,2. This process can be observed in all kingdoms of 
life as part of evolution3, and it occurs also in humans4,5. Evolution is not only the result 
of gene loss, but also gene duplication as observed in eukaryotes, such as plants and 
vertebrates6. During the evolution of vertebrates, humans acquired genes from bacteria 
through horizontal gene transfer. In fact, almost half of the human genome is derived 
from transposable elements, that fortunately have become inactive7. Intriguingly, some 
prokaryotes have experienced higher rates of gene loss than of gene acquisition, a trend 
that is observed particularly among genes belonging to the same family8. This loss of 
genes can compromise the free-living status of the respective organisms and facilitate 
intracellular lifestyles, ultimately leading to the development of parasites, 
endosymbionts and organelles. For instance, during evolution, chloroplasts transferred 
more than 3000 protein-encoding genes to their host. Thus, many proteins required for 
chloroplast function are synthetized by the host, and subsequently imported from the 
host’s cytoplasm into the organelle. Chloroplasts have conserved ~100 protein-encoding 
genes which, overall, encode mostly proteins that are difficult to transport across the 
chloroplast’s outer, inner and thylakoid membranes9. Chloroplasts and mitochondria 
are the current end points of an extreme reductive evolution that started with 
endo-symbiotic bacteria. For other microorganisms this evolution has reached an 
intermediate stage as exemplified by Buchnera aphidicola. This bacterium is an obligate 
symbiont, which lives in the gut of aphids. The presence of B. aphidicola is advantageous 
for the host, because it provides essential amino acids that are insufficiently provided 
through the diet of the aphids. Remarkably, Buchnera species evolved from the same 
ancestor as Escherichia coli (4.6 Mbp) and became an example of extreme genome 
reduction with genome sizes of approximately 600 kb10. Bacteria with intracellular 
lifestyles do not necessarily provide benefits to their hosts. Wolbachia species, which 
infect insects and transfer genes to their host, are able to modify the mating behaviour 
of the host by increasing female promiscuity to enhance their transmission to other 
hosts11.  
The examples above refer to organisms that have adapted to different conditions 
over several million years. However, genome reduction is not a process that exclusively 
occurs in nature since, in recent years, it has also been achieved in the laboratory by 
human efforts. This became possible as a result of the advances that have been achieved 
in genome sequencing and genome engineering in approaches that are collectively 
referred to as synthetic biology. Thus, the complete chemical synthesis of bacterial 
genomes has been achieved with the construction of Mycoplasma mycoides JCVI-syn1.0 
and its minimized version JCVI-syn3.0 (531 kbp)12,13. Originally, genome reduction in the 
context of synthetic biology was primarily aimed at determining the minimal set of 
genes necessary to maintain cell viability and at elucidating gene functions14,15. However, 
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at the same time, it was realized that genome reduction could also offer the possibility 
to create novel chassis that could be exploited as bacterial cell factories16,17. 
Design-Build-Test cycle 
The construction and improvement of genome-reduced microorganisms involves 
the Design-Build-Test cycle abbreviated as DBT cycle (Figure 1.1)18. The process begins 
with the design of a desired cell factory. Ideally, such a cell factory produces high yields 
of particular value-added products, utilizes low-cost substrates and presents an optimal 
productivity with minimal resource expenditure on biomass formation19. These 
preferred traits should be accompanied by low maintenance requirements in 
fermentation and high-level product secretion into the growth medium for ease of 
downstream processing of products. Some target sequences to be excluded from the 
final engineered genome include protease genes, transposons and insertion sequences, 
prophage regions and non-essential genes. Protease-deficient cell factories can improve 
the yields of protein products20. Deletion of non-essential genes, such as redundant 
genes, prophage regions or flagellar genes, may prevent the inefficient use of resources 
and enhance the stability of the producing cells. While, deletion of transposons and 
insertion sequences will increase their genetic stability21. The essentiality of genetic 
elements can be tested by inactivation through homologous recombination, transposon 
insertions, antisense RNA expression, or the CRISPRi technology22,23. Once the target 
genes for deletion have been defined, the following step in the process is to build the 
desired genome. However, in this context, it is necessary to consider the possibility of 
synthetically lethal genome configurations as a consequence of the simultaneous 
deletion of genes that are by themselves non-essential24. Lastly, the construction of the 
envisaged genome can be achieved along two major routes that involve either 
bottom-up or top-down approaches. The bottom-up approach requires chemical 
synthesis of DNA fragments and their consecutive assembly to create the desired 
genome25. Streamlining a genome through a top-down approach entails the successive 
excision of genomic segments26. To note, most of the genome-reduced microorganisms 
so far have been created following top-down approaches.  
The next step in the DBT cycle requires to test the characteristics of the newly 
engineered strain. The performance of the strain should be evaluated to ensure that it 
meets the desired requirements. The acquired knowledge from this evaluation is 
fundamental for further improvement of the design. Since living cells display many 
different layers of regulation, whose intricate interactions are far from being completely 
understood, iterative DBT cycles will be required for fine-tuning and delivery of the 
ultimate cell factory. 
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Microbial cell factories 
Although the use of genome-reduced cell factories has been explored in different 
microorganisms, most efforts have addressed prokaryotic cells (Figure 1.2). The genome 
engineering of eukaryotic cells is currently also in progress, but it is complicated due to 
the cellular complexity as illustrated by a relatively modest genome reduction of ~5% in 
Saccharomyces cerevisae27. E. coli and B. subtilis, the main model organisms of 
Gram-negative and Gram-positive bacteria, respectively, are currently preferred targets 
for genome engineering. This has resulted in genome-reduced derivative E. coli strains 
that lack up to 36% of the genome, and B. subtilis strains that lack up to 42% of the 
genome28,29. Importantly, cell factories with reduced genomes have already shown 
beneficial traits compared to their parental strains. For instance, a derivative of  
Streptomyces avermitilis, lacking 18.5% of the genome, displays increased antibiotic 
production due to the selective deletion of genes involved in the production of the 
major endogenous secondary metabolites produced by the parental strain30. Also, the 
E. coli strain MGF-01 displayed increased threonine production after the removal of 
genes that are not required for growth in minimal media31. Unfortunately, the acquired 
properties of genome-reduced strains are not always beneficial for their application in 
biotechnology. Some genome-engineered strains display inferior growth compared to 
the respective parental strains, or show no improvement in productivity32. 
 
Figure 1.1 | Design–Build-Test cycle. Engineering of microorganisms by means of the DBT cycle. Properties 
that can be considered for the design of the cell factory include removal of non-essential or even 
detrimental genes that impose a metabolic burden on the cell. The second step involves the construction 
of the desired genome. To verify whether the design is functional, strains should be thoroughly tested. 
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Figure 1.2 | Maximal reported microbial genome reductions without loss of productivity. The Figure 
indicates the names of the parental strains used in different top-down genome engineering efforts, where 
the resulting genome-reduced strains showed enhanced features for biotechnological applications. It 
should be noticed that in some of the indicated strains even larger sections of the genome have been 
deleted, but these have not yet been tested for application potential, or they showed no improvements in 
productivity. Therefore, the latter engineered strains were not considered for this comparison.  
Bacillus subtilis as a cell factory 
Bacillus species have been used extensively in industry for enzyme production, 
mainly because of their high secretion capacity and genetic amenability. Particularly, 
B. subtilis is a preferred cell factory as many of its products are ‘Generally Recognised As 
Safe’ by the Food and Drug safety Authority of the USA. The latter relates to the 
complete absence of toxins from B. subtilis, especially the lipopolysaccharides 
(endotoxins) produced by Gram-negative bacteria such as E. coli. However, a clear 
limitation of B. subtilis is its natural high-level production of proteases that can severely 
hamper the production of both homologous and heterologous proteins. Attempts to 
overcome this limitation resulted in the creation of the protease-deficient strains BRB08 
and WB800, which lack the genes for the eight major extracellular proteases of 
B. subtilis 16833,34. From all industrially employed Bacillus species, genome reduction 
efforts have only been documented for B. subtilis. This is exemplified by the B. subtilis 























cellulase and a subtilisin-like protease to similar levels as the parental 168 strain35. In 
contrast, another derivative of B. subtilis 168, namely strain MGB874 with a genome 
reduction of 20.7%, showed increased production of the secreted alkaline cellulase 
Egl-237 by about 2-fold36.  
A relatively recent systematic reduction of the B. subtilis 168 genome has resulted 
in the so far largest documented genome reduction of 42.3%29. The construction of this 
strain involved many consecutive deletion steps resulting in the delivery of a large 
collection of strains lacking different genomic regions. The PhD research described in 
this dissertation is built on investigations where different intermediate strains from this 
collection were characterised for their potential application in protein production. 
Major attention was focused on three genome-reduced strains in particular, which will 
be referred to in this thesis as midiBacillus-I, midiBacillus-II and miniBacillus. The genomes 
of these strains have been reduced by approximately 26%, 31% and 35%, respectively, 
compared to the parental strain26 (Figure 1.3).  
 
Figure 1.3 | Phylogeny of the genome-reduced B. subtilis strains used in the present PhD research. 
B. subtilis strain 168 is the parental strain from which the ∆6, midiBacillus-I, midiBacillus-II and miniBacillus 
strains were created. The respective genome reduction is indicated as a percentage of the genome of the 
parental strain 168. 
 
 
The first steps towards this massive genome reduction in B. subtilis included a 
systematic gene function analysis and the subsequent rational deletion of five 
prophages and prophage-like regions, as well as the large pks operon15,37. Plasmid-based 
chromosomal integration-excision systems were used to delete the latter regions, 
resulting in the so-called ∆6 strain37. Prophage-free strains have led to promising results 
for industrial applications, as reported for Corynebacterium glutamicum38. The 
subsequent markerless B. subtilis strains with step-wise reduced genomes were 
constructed with the help of a counter-selection system based on the mannose 
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manP, which encodes a mannose transporter, and manA, whose product is an 
isomerase, were deleted from the ∆6 strain. The manP gene, a spectinomycin resistance 
gene and the flanking sequences of the respective regions to be deleted were then 
inserted in a shuttle vector. To corroborate the integration into the chromosome, clones 
were first selected based on spectinomycin resistance. To check the subsequent 
excision of the plasmid, cells were grown on mannose, since these cells that are 
manA- and manP-deficient will be resistant to mannose. Additionally, a vector containing 
the ccdB gene under the control of a rhamnose promoter from E. coli was used for the 
construction of this series of strains with reduced genomes26. The genomic regions 
deleted in this process correspond to additional prophages regions, and genes required 
for the production of the antibiotics sublancin, subtilosin A, bacilysin and bacilysocin. 
Other deleted genes are involved in motility, metabolism of secondary carbon sources, 
sigma factors for sporulation, proteases genes, and genes of unknown function. As 
pointed out above, some bacterial features that are required for survival and 
competitive success in nature are unnecessary under production conditions, as 
exemplified by flagella. Other processes, like sporulation, are unwanted for industrial 
strains, as spores facilitate more readily the release of genetically modified strains into 
the environment, or allow isolation of valuable production strains from commercialized 
products. Moreover, considering that protein synthesis is an expensive process, the 
deletion of unnecessary or redundant genes could decrease the respective energy 
demands and would allow the re-routing of resources towards products40.  
Staphylococcal antigens as model proteins 
As model proteins for production in the genome-reduced B. subtilis strains, the 
focus in the present PhD research was directed towards antigens from the human and 
livestock pathogen Staphylococcus aureus. This Gram-positive bacterium has acquired 
many different antimicrobial resistances and is estimated to account for 700 000 deaths 
per year, making it one of the top-10 threats to global health41. One of the strategies to 
combat antibiotic resistant pathogens is vaccination, and for this purpose adequate 
antigens are needed to trigger and boost the immune system42. However, currently 
there is no clinically approved vaccine available to prevent infections by this pathogen43. 
In principle, S. aureus displays and secretes a broad repertoire of proteins that could be 
used as antigens for vaccination. Four of these potential antigens were selected as 
reporter proteins for the here presented studies, namely: the chemotaxis inhibitory 
protein (CHIPS), the staphylococcal complement inhibitor (SCIN), the nuclease (Nuc) 
and the immunodominant staphylococcal antigen A (IsaA). While these four proteins 
served primarily to assess improvements in secretion by genome-reduced B. subtilis 
strains, they may also have future potential applications as targets in 
anti-staphylococcal immunotherapies or as diagnostic markers44–46.  
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Scope of this dissertation 
Dear reader of this thesis, 
When looking for strategies to improve secretory protein production, one could 
go from the optimization of culture and fermentation conditions, via the selection of 
optimal promoters, ribosomal-binding sites and signal peptides, or the editing of 
metabolic pathways, to genome engineering. However, the central question that was 
directly addressed in the present PhD research was whether the massive 
genome-reductions already achieved in the midiBacillus-I, midiBacillus-II and miniBacillus 
strains would allow improved protein production, and if so, which mechanisms would 
be hidden behind such improvements. Upon reading this dissertation, you will realize 
that it focuses mostly on the third step of the DBT cycle. This goes in hand with the three 
main objectives of this thesis, which were: 1. benchmarking genome-reduced B. subtilis 
strains as potential cell factories for the production of staphylococcal antigens; 2. 
identifying beneficial or non-favourable traits presented by B. subtilis strains with 
reduced genomes; and 3. defining the mechanisms underlying the observed effects on 
protein productivity.  
One of the main characters is presented in Chapter 2 of this thesis: the B. subtilis 
strain PG10, also known as miniBacillus. It is worthy to note that miniBacillus is the most 
genome-reduced Gram-positive bacterium so far used as a cell factory. It lacks 35% of 
the genome compared to its parental strain B. subtilis 168. Notwithstanding this massive 
genome reduction, miniBacillus outperformed its parental strain in the heterologous 
production and secretion of the four antigens IsaA, Nuc, CHIPS and SCIN from the 
human pathogen S. aureus. 
Our second main character, in the order of appearance in this thesis but not in 
importance, is the B. subtilis strain IIG-Bs27-47-24, referred to as midiBacillus-II. This 
strain belongs to the same phylogeny as miniBacillus. However, its genome was only 
reduced by 31% compared to the parental strain 168. For the studies described in 
Chapter 3, a novel mass-spectrometry approach was exploited for absolute protein 
quantification, firstly to define the membrane proteome of midiBacillus-II. Secondly, the 
approach was used to define changes in the membrane upon secretion of IsaA by 
midiBacillus-II. The resulting quantitative dataset offered an unprecedented view of the 
secretion stress responses displayed by midiBacillus-II. 
To disclose major cellular adaptations and to point out possible differences 
displayed by midiBacillus-II and its parental strain upon secretory protein production, 
the physiological changes in both strains were analysed through label-free protein 
quantification as described in Chapter 4. In addition to membrane proteins, also changes 
in the levels of cytosolic and extracellular protein were investigated for a 
comprehensive proteomic survey. The major changes are described in Chapter 4 with 
special focus on protein synthesis, stress responses and protein secretion. 
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Chapter 5 introduces the third main character in the present thesis, namely 
B. subtilis strain IIG27-39-1, the midiBacillus-I. The midiBacillus-I was also challenged to 
produce IsaA, but in a special setting. Here it is important to note that the 
characterization of Bacillus strains in a shake flask provides merely a ‘sneak preview’ of 
their potential for industrial application. Instead, cultivation in bioreactors offers the 
possibility to test the strain under controlled conditions that are more similar to the 
industrial settings47. midiBacillus-I cells were therefore grown in laboratory-scale 
bioreactors, where several physiological parameters were measured and compared to 
the parental strain 168. 
After reading about the characterization of the genome-reduced B. subtilis strains, 
especially miniBacillus, midiBacillus-I and midiBacillus-II, you will arrive to the last part of 
this thesis, Chapter 6. Here, I present the main conclusions that can be drawn from the 
documented studies, and provide directions for future investigations towards 
genome-engineered B. subtilis production strains.  




Rocío Aguilar Suárez 
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